17th North American Regional ISSX Meeting (October 16 - 20, 2011): Mechanisms of Xenobiotic Toxicities

P216

A Comparative Kinetic Study Of [14C]-Eugenol And [14C]-Methyleugenol Activation And Detoxification In Human, Mouse, And Rat Liver Fractions
Emmanuel Minet, British American Tobacco; Daniela Gentile, Charles River Laboratories; Clive Meredith, British American Tobacco; Nik Newland, British American Tobacco; Eian Massey, British American Tobacco

P217

A Simple, Robust Automated Multiplexed Cell-Based Assay Process for the Assessment of Mitochondrial Dysfunction and Cytotoxicity
Bradley R. Larson, BioTek Instruments; Peter Banks, BioTek Instruments; Tracy Worzella, Promega Corporation; Timothy A. Moeller, Celsis In Vitro Technologies; Andrew Niles, Promega Corporation

P218

A fluorescence based screening approach for determination of drug-phospholipid complex formation and prediction of phospholipidosis
Liping Zhou, Novartis Institutes for Biomedical Research Inc.; Gina Geraci, Novartis Institutes for Biomedical Research Inc.; Linhong Yang, Novartis Institutes for Biomedical Research Inc.; Jianling Wang, Novartis Institutes for Biomedical Research Inc.; Upendra A. Argikar, Novartis Institutes for Biomedical Research Inc.

P219

A novel in vitro approach for risk assessment of reactive metabolites in Drug Discovery
Richard A. Thompson, AstraZeneca R&D Molndal; Emre M. Isin, AstraZeneca R&D Molndal; Yan Li, AstraZeneca; Lars Weidolf, AstraZeneca R&D Molndal; Ian Wilson, AstraZeneca; Ken Page, AstraZeneca; Steve Swallow, AstraZeneca; Gerry Kenna, AstraZeneca

P220

Bioactivation and Dehydrogenation of Naltrexone and Oxycodone in Human Liver Microsomes: Identification of the Reactive Quinone Methide Species
Bo Wen, Hoffmann-La Roche; Jiansheng Huang, Hoffmann-La Roche; David Moore, Hoffmann-La Roche Inc.

P223

Effect on GSH and GSSG Levels in Rats Treated with Acetaminophen and Tamoxifen Using LC-MS/MS
Helen L. Shen, QPS, LLC; Lata Venkatarangan, QPS, LLC; Bruce Aungst, QPS, LLC; Zamas Lam, QPS, LLC

P225

Intrauterine Origin of Caffeine-Induced High Susceptibility to Adult Metabolic Syndrome: Alleviated Glucocorticoid Inactivation Alters the Neuroendocrine Metabolic Programming of Fetal Rats
Dan Xu, Basic Medical School of Wuhan University, Wuhan 430071, China; Benjian Zhang, Basic Medical School of Wuhan University, Wuhan 430071, China; Jie Ping, Basic Medical School of Wuhan University, Wuhan 430071, China; Gai Liang, Basic Medical School of Wuhan University, Wuhan 430071, China; Fang Liu, Basic Medical School of Wuhan University, Wuhan 430071, China; Hao Kou, Basic Medical School of Wuhan University, Wuhan 430071, China; Xiao-jun Li, Basic Medical School of Wuhan University, Wuhan 430071, China; You-ying Lei, Basic Medical School of Wuhan University, Wuhan 430071, China; Hui Wang, Basic Medical School of Wuhan University, Wuhan 430071, China

P226

Pyrrolizidine Alkaloids Induce Fetal Developmental Toxicities in Mice
Hao Kou, Basic Medical School of Wuhan University, Wuhan 430071, China; Jie Xiong, Basic Medical School of Wuhan University, Wuhan 430071, China; Zhen-guo Ma, Basic Medical School of Wuhan University, Wuhan 430071, China; Jiang Zheng, University of Washington; Yu Guo, Basic Medical School of Wuhan University, Wuhan 430071, China; Hui Wang, Basic Medical School of Wuhan University, Wuhan 430071, China

P227

Risk Assessment for Idiosyncratic Hepatotoxicity of a BACE1 Inhibitor by Covalent Binding in Human S9 Fractions
Louis Leung, Pfizer Inc.; Zhuang Miao, Pfizer Inc.; Michael Brodney, Pfizer Inc.; Kevin Ogilvie, Pfizer Inc.; Klass Schildknegt, Pfizer Inc.; JianHua Liu, Pfizer Inc.; R. Scott Obach, Pfizer Inc.

P229

THYROXINE (T₄) CATABOLISM IN HUMAN AND RAT HEPATOCYTES INCREASES FOLLOWING EXPOSURE TO PROTOTYPICAL HEPATIC ENZYME INDUCERS
Vicki M. Richardson, USEPA and UNC at Chapel Hill; Yusupha M. Sey, USEPA; Michael J. DeVito, NIEHS/NTP

P230

Zomepirac Acyl Glucuronide Migration
Rongfang Fran Xu, Johnson & Johnson Pharmaceutical Research and Development; Heang Keang Lim, Johnson & Johnson Pharmaceutical Research and Development; Michael McMillian, Johnson & Johnson Pharmaceutical Research and Development, LLC.